Targeted adjuvant therapy in breast cancer

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Endocrine therapy first demonstrated molecular targeted therapy's potential in early-stage breast cancer (BC).
• Trastuzumab-based HER2 blockade significantly altered the natural history of HER2-positive BC.
• Ongoing research aims to enhance adjuvant targeted therapies for BC by targeting key oncogenic drivers of minimal residual disease.

Purpose of the Study:

• To review current targeted adjuvant therapeutic strategies in breast cancer.
• To explore ongoing efforts to augment the efficacy of HER2 blockade in HER2-positive BC.
• To discuss challenges and potential solutions for developing targeted agents in the adjuvant setting.

Main Methods:

• Extensive literature search of PubMed.
• Review of targeted adjuvant therapeutic strategies including HER2 blockade, angiogenesis inhibition, PI3K-mTOR-AKT pathway inhibition, CDK4/6 inhibition, and PARP inhibition.
• Analysis of clinical development challenges and potential solutions.

Main Results:

• The review covers multiple targeted adjuvant therapies for breast cancer.
• HER2 blockade has a proven track record, with ongoing efforts to improve its efficacy.
• Other targeted pathways (angiogenesis, PI3K-mTOR-AKT, CDK4/6, PARP) are under investigation.

Conclusions:

• Targeted agents hold significant potential to improve clinical outcomes in early-stage breast cancer.
• Systematic assessment of minimal residual cancer burden is crucial for successful clinical development of adjuvant targeted therapies.
• Overcoming challenges in clinical development is key to realizing the full potential of targeted agents in BC.